https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-discontinuation-strides-phase-2-clinical
https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1
https://ir.bioagelabs.com/news-releases/news-release-details/bioage-announces-170-million-oversubscribed-series-d-financing
https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-initiation-phase-2-embraze-trial
https://ir.verupharma.com/news-events/press-releases/detail/222/veru-announces-meta-analysis-of-body-composition-data-from
https://investor.lilly.com/news-releases/news-release-details/treatment-tirzepatide-adults-pre-diabetes-and-obesity-or
Veru data simplified from previous L-S proprietary reports.
https://ir.bioagelabs.com/static-files/85d8c598-5048-42cd-9f64-6842b1433ac1
https://ir.verupharma.com/news-events/press-releases/detail/218/veru-reaches-full-enrollment-for-phase-2b-quality-clinical
